

## The role of endoscopy in the management of choledocholithiasis

*This is one of a series of statements discussing the use of GI endoscopy in common clinical situations. The Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE) prepared this text. In preparing this guideline, a search of the medical literature was performed using PubMed. Additional references were obtained from the bibliographies of the identified articles and from recommendations of expert consultants. When few or no data exist from well-designed prospective trials, emphasis is given to results of large series and reports from recognized experts. Guidelines for appropriate use of endoscopy are based on a critical review of the available data and expert consensus at the time the guidelines are drafted. Further controlled clinical studies may be needed to clarify aspects of this guideline. This guideline may be revised as necessary to account for changes in technology, new data, or other aspects of clinical practice. The recommendations were based on reviewed studies and were graded on the strength of the supporting evidence (Table 1).<sup>1</sup> The strength of individual recommendations is based on both the aggregate evidence quality and an assessment of the anticipated benefits and harms. Weaker recommendations are indicated by phrases such as “we suggest,” whereas stronger recommendations are typically stated as “we recommend.”*

*This guideline is intended to be an educational device to provide information that may assist endoscopists in providing care to patients. This guideline is not a rule and should not be construed as establishing a legal standard of care or as encouraging, advocating, requiring, or discouraging any particular treatment. Clinical decisions in any particular case involve a complex analysis of the patient's condition and available courses of action. Therefore, clinical considerations may lead an endoscopist to take a course of action that varies from these guidelines.*

Gallstone disease affects more than 20 million American adults<sup>2</sup> at an annual cost of \$6.2 billion.<sup>3</sup> The incidence of choledocholithiasis ranges from 5% to 10% in those patients undergoing laparoscopic cholecystectomy for symptomatic cholelithiasis<sup>4-7</sup> to 18% to 33% of patients with acute biliary pancreatitis.<sup>8-11</sup> The diagnostic approach to patients with suspected choledocholithiasis is addressed

in a separate ASGE practice guideline.<sup>12</sup> This guideline addresses the role of endoscopy in the management of patients with known choledocholithiasis.

Although data regarding the natural history of choledocholithiasis are limited, available studies indicate that 21% to 34% of common bile duct (CBD) stones will spontaneously migrate,<sup>13,14</sup> and migrating stones pose a moderate risk of pancreatitis (25%-36%)<sup>13,14</sup> or cholangitis if they obstruct the distal duct.<sup>15</sup> The natural history of CBD stones incidentally discovered during routine intraoperative cholangiography (IOC) at elective cholecystectomy may be less morbid than symptomatic CBD stones discovered pre-cholecystectomy.<sup>16</sup> However, because biliary pancreatitis and cholangitis may be life-threatening conditions, removal of discovered CBD stones is generally recommended.<sup>17,18</sup>

### ENDOSCOPIC RETROGRADE CHOLANGIOGRAPHY (ERC)

Endoscopic retrograde cholangiography (ERC) with endoscopic sphincterotomy (ES) and stone extraction was first described in 1974<sup>19</sup> and has been a first-line management strategy for choledocholithiasis for the past 2 decades. In diverse settings, including community practice, reported success rates for removing CBD stones at ERC have commonly ranged from 87% to 100%,<sup>20-26</sup> with acceptably low rates of morbidity (~5%).<sup>21,27,28</sup>

### Timing of ERC and relationship with cholecystectomy

The optimal timing for therapeutic ERC in the management of choledocholithiasis is variable and depends on the specific clinical scenario. Although acute cholangitis should generally lead to an expeditious ERC, the degree of procedure urgency depends on the clinical severity; consensus criteria for defining the severity of acute cholangitis have been proposed.<sup>29</sup> Truly urgent ERC is indicated when obstructing biliary stones are associated with severe acute cholangitis that is not responding to intravenous antibiotics and fluid resuscitation.<sup>29-31</sup> In these instances, biliary drainage is the primary focus of management rather than stone extraction. Early ERC (variably defined, but generally <72 hours) is advocated for patients with moderately severe acute cholangitis who are clinically responding to medical therapy.<sup>29,31</sup> Early ERC has also been advocated for patients with acute biliary pancreatitis and clinical evidence of biliary

**TABLE 1. GRADE system for rating the quality of evidence for guidelines**

Quality of evidence	Definition	Symbol
High quality	Further research is very unlikely to change our confidence in the estimate of effect.	⊕⊕⊕⊕
Moderate quality	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.	⊕⊕⊕○
Low quality	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.	⊕⊕○○
Very low quality	Any estimate of effect is very uncertain.	⊕○○○

Adapted from Guyatt et al.<sup>1</sup>

obstruction (yet not cholangitis)<sup>32</sup> and for patients with predicted severe acute biliary pancreatitis,<sup>33-35</sup> as some randomized trials have shown reduced morbidity in these patient groups. However, other trials have not shown a benefit of early ERC in these patient groups,<sup>36,37</sup> and thus uncertainty remains. These data are discussed in more detail in the aforementioned ASGE guideline on the role of endoscopy in the evaluation of suspected choledocholithiasis.<sup>12</sup>

When ERC is selected as a management strategy for CBD stones in the setting of a planned laparoscopic cholecystectomy, several options exist with regard to the sequencing of these procedures. Preoperative ERC for patients with a high likelihood of choledocholithiasis<sup>38,39</sup> or intraoperative<sup>40,41</sup> or postoperative ERC<sup>42,43</sup> for patients with a positive IOC have all been described, without conclusively superior outcomes with any one strategy.<sup>40</sup> A single randomized trial of patients at intermediate risk of choledocholithiasis prospectively compared routine preoperative ERC and selective postoperative ERC; there was no difference in the rates of ductal clearance.<sup>44</sup> However, each ERC-associated strategy is associated with some caveats. With preoperative ERC, there remains a risk of interval migration of additional gallbladder stones before cholecystectomy,<sup>45</sup> and indiscriminant/routine use of preoperative ERC unnecessarily exposes patients to the risks of ERC. Intraoperative ERC is, by definition, on demand and logistically impractical for most gastroenterologists to offer to their surgical colleagues. Centers that have used this approach typically have surgeons capable of performing ERC. Last, the downside to postoperative ERC for stone clearance is the risk of technical failure, potentially requiring reoperation for duct exploration and clearance<sup>1</sup>; as such, this strategy may be optimally used in centers with significant expertise in ERC.

If preoperative ERC is undertaken for choledocholithiasis, laparoscopic cholecystectomy ideally should be performed within 2 weeks because longer delays have been associated with cholecystitis, biliary colic, recurrent choledocholithiasis, gallstone pancreatitis, and a trend toward higher rates of conversion to open cholecystectomy in multiple retrospective analyses.<sup>47-50</sup> Further, in a recent randomized trial of early (<72 hours) versus delayed (6-8

weeks) laparoscopic cholecystectomy in 96 patients status post endoscopic CBD stone clearance, a 36% incidence of recurrent biliary events (mostly biliary colic and acute cholecystitis) was reported in the delayed surgery arm.<sup>51</sup> This was significantly higher morbidity compared with the early surgery group and necessitated emergency surgery in 24% (4/17) of those patients who experienced a recurrent biliary event.

Early reports indicated that recurrent biliary complications after ES and stone clearance developed in a minority (12%) of patients with choledocholithiasis.<sup>52</sup> However, multiple subsequent randomized, controlled trials have addressed the issue of prophylactic cholecystectomy after ERC versus a watch-and-wait approach to the gallbladder. A systematic review of these trials reported higher rates of mortality, jaundice, or cholangitis; recurrent biliary pain; and the need for further cholangiography in those patients assigned to watch-and-wait, of whom 35% eventually required cholecystectomy.<sup>53</sup> As such, cholecystectomy is recommended for most patients with cholelithiasis after ductal clearance by ERC, particularly given the relatively low morbidity of laparoscopic cholecystectomy.

### Preparation and cholangiography

In preparation for ERC, antibiotic prophylaxis is unnecessary in the majority of patients with suspected choledocholithiasis, unless cholangitis or immunosuppression is present or biliary drainage is predicted to be incomplete; a relevant ASGE guideline covers this topic in detail.<sup>54</sup> Proper technique for cholangiographic imaging is essential for successful identification of stones at ERC.<sup>55</sup> Despite careful attention to technique, the sensitivity of cholangiography for choledocholithiasis is imperfect (89%-93%)<sup>56,57</sup>; false-negative ERCs usually occur when small stones are present in a dilated duct. When a stone is anticipated, yet not seen on cholangiography, the endoscopist often must decide whether to perform an empirical ES to facilitate duct sweeping. Although empirical ES and sweeping may increase the detection rate of small (<5 mm) stones, it is of uncertain clinical benefit,<sup>58</sup> although perhaps beneficial in the setting of cholangitis.<sup>59</sup> The risks of a missed stone must be weighed against the potential

complications of an unnecessary sphincterotomy. This decision will also be influenced by the pretest probability for choledocholithiasis, the quality of fluoroscopy used, and the availability of potentially helpful ancillary techniques such as intraductal US or standard EUS. Various methods for sonographically guided biliary endotherapy using a single echoendoscope have yielded promising early results, but these approaches remain investigational at this time.<sup>60,61</sup>

### **ES and endoscopic papillary balloon dilation (EPBD)**

When 1 or more stones are identified at cholangiography, successful extraction typically requires either ES or EPBD, unless the stones are very small.<sup>62</sup> Endoscopic papillary balloon dilation (EPBD) does not permanently ablate the sphincter choledochus and thus was initially proposed as an alternative to ES with potentially less long-term morbidity.<sup>23</sup> However, multicenter randomized controlled trials,<sup>63</sup> systematic reviews<sup>64,65</sup> and a large prospective ERC series<sup>66</sup> demonstrated a significantly higher risk of pancreatitis with EPBD in addition to poorer technical success for stone clearance and more frequent need for mechanical lithotripsy. As such, primary EPBD is not advocated for routine use, although it may be a reasonable option in select circumstances, eg, coagulopathy, periampullary diverticulum, or surgically altered anatomy that increases the difficulty of ES.<sup>67-69</sup> EPBD after ES is discussed in the following.

ES may be performed using either pure cutting current or blended cutting/coagulation current. Although some trials suggested a reduced frequency of post-ERCP pancreatitis with pure cutting current,<sup>70,71</sup> a recent meta-analysis found no difference in pancreatitis incidence between the 2 modalities, and pure cutting current was associated with a higher risk of bleeding.<sup>72</sup> The appropriate length of the sphincterotomy may be variable depending on papillary anatomy and the size of the stone(s), but should not extend beyond the duodenal transverse fold. Occasionally, a stone will be encountered that is impacted in the ampulla, making traditional biliary cannulation and ES difficult or impossible. In these cases, needle-knife sphincterotomy is frequently effective in disimpacting the stone, and the underlying stone likely adds some margin of safety in protecting the pancreatic sphincter from inadvertent cautery.<sup>73</sup>

### **Stone extraction and biliary drainage**

Extraction of stones may be undertaken using either balloon catheters or wire baskets. Although no data directly compare their efficacy for uncomplicated CBD stones, balloons are typically the first-line device, given the ease of use, utility in occlusion cholangiography, and the lack of risk of becoming entrapped in the duct. Biliary stone extraction devices are the subject of an ASGE technology review.<sup>74</sup> In addition to an adequate ES, surveil-

lance for benign, stone-associated CBD strictures must be undertaken because these strictures must be addressed before stone extraction is possible.<sup>75,76</sup> Multiple stones should be extracted one at a time, starting with the distal-most stone first; attempts to extract multiple stones at once may result in impaction.<sup>77</sup> In cases of incomplete stone extraction or severe acute cholangitis, a biliary endoprosthesis should be placed to ensure adequate biliary drainage. Plastic biliary stents appear to be as effective as nasobiliary drainage catheters in the management of ascending cholangitis.<sup>78-80</sup> In cases of incomplete stone extraction, stent placement may have some therapeutic benefit on the CBD stone(s) in addition to securing drainage; in many instances, difficult biliary stones may be smaller, fragmented, or even absent after a period of stenting.<sup>81-83</sup> However, biliary stenting as a definitive therapy for difficult bile duct stones should be approached with caution. In 4 studies comprising a total of 228 patients, frail and/or elderly patients with CBD stones resistant to endoscopic removal were treated with plastic biliary stent placement.<sup>84-87</sup> Biliary-associated morbidity (mostly cholangitis) rates of 36% to 63% and biliary-associated mortality rates of 6% to 21% were reported during median follow-up times of 20 to 39 months. As such, biliary stenting as a stand-alone therapy for choledocholithiasis should be reserved for highly selected cases (eg, short life expectancy).

### **Failed biliary access**

In a subset of patients with known choledocholithiasis, ERC is unsuccessful because of failure to access the CBD. Although several reasonable options exist for subsequent management, the course of action chosen will depend on several factors including the reason(s) for failure (eg, aberrant anatomy), the presence or absence of cholangitis, the medical stability and performance status of the patient, whether cholecystectomy is planned, and, perhaps most importantly, available expertise. Both a repeat attempt by the same endoscopist on a different day<sup>88</sup> or referral to a tertiary center with significant ERC expertise<sup>89</sup> may be reasonable options and have both been reported to have high rates (88%-96%) of selective cannulation in patients with previous failed ERC. Percutaneous transhepatic cholangiography (PTC) has been used to facilitate ERC via transpapillary guidewire passage, also known as rendezvous procedure, with the ERC performed either at the time of initial PTC<sup>90</sup> or after a few days of percutaneous biliary drainage.<sup>91</sup> PTC has also been used for primary percutaneous therapy of stones after failed ERC, although frequently multiple sessions are required, particularly if large or multiple bile duct stones are encountered.<sup>92</sup> EUS-guided transenteric biliary puncture and a rendezvous procedure have also been described after failed ERC for choledocholithiasis,<sup>93</sup> but the safety profile of this technique is not fully understood, and, at present, it is best reserved for use at tertiary centers with significant experience in EUS and ERC. In medically fit patients with cho-

**TABLE 2. Clinical situations associated with difficult bile duct stone extraction**Stones >15 mm<sup>20,98</sup>

Stones that cannot be captured in a basket for extraction or mechanical lithotripsy

Stones associated with complex biliary strictures (eg, primary sclerosing cholangitis, recurrent pyogenic cholangitis), including hepatolithiasis<sup>220,221</sup>Stones in patients with surgically altered upper gut anatomy (eg, Roux-en-Y gastric bypass, Billroth II gastrojejunostomy)<sup>222,223</sup>Mirizzi syndrome<sup>224</sup>

ledocholithiasis, surgical intervention is frequently appropriate after failed ERC (or as a primary management approach, discussed in detail in the following), particularly when cholecystectomy is also required. Surgical options include both open and laparoscopic CBD exploration and the so-called laparoendoscopic rendezvous procedure, during which a guidewire is passed via the cystic duct and into the duodenum to facilitate intraoperative ERC.<sup>94</sup>

## COMPLICATED BILIARY STONE DISEASE

Approximately 85% to 90% of biliary stones can be removed with a balloon or basket after ES or EPBD.<sup>20,95</sup> Almost by definition, those stones that defy initial efforts represent difficult stones. However, some prespecified clinical factors are associated with increasing procedure difficulty and poorer success rates in the endoscopic management of choledocholithiasis.<sup>20,68,96-98</sup> Table 2 lists clinical scenarios that are considered to be complicated biliary stone disease. Although duodenal diverticula are associated with an increased incidence of choledocholithiasis,<sup>99,100</sup> they have generally not been shown to lower the success rate of biliary cannulation or stone removal,<sup>101-103</sup> although some studies report higher rates of postsphincterotomy bleeding.<sup>104</sup> Other factors, including the degree of angulation of the distal CBD,<sup>104</sup> have been proposed to increase the difficulty of endoscopic stone removal, but not robustly evaluated. Some of the factors that predict difficulty can be identified pre-ERC and thus have implications for consideration of referral to a tertiary center or alternative management approaches. Potential endoscopic management strategies to address these clinical problems are discussed later.

### Large bile duct stones

Common bile duct stones larger than 10 mm in diameter<sup>23</sup> and especially stones larger than 15 mm in diameter are associated with a lower success rate of endoscopic extraction and a greater need for some form of lithotripsy

to facilitate removal.<sup>20,98</sup> Various techniques have been described to assist in the management of large bile duct stones.

**EPBD after ES.** EPBD after ES using 12- to 20-mm esophageal or pylorus-type balloons was first described in 2003 as a useful technique to manage large bile duct stones or stones above a tapering distal CBD.<sup>105</sup> Several subsequent reports have described a safety experience that appears comparable to ES alone; the higher pancreatitis rates seen with primary EPBD may be mitigated by the preceding ES with this technique, and rates of bleeding and perforation also do not appear to be increased.<sup>106-111</sup> Although 1 nonrandomized trial found a reduction in fluoroscopy time and less need for mechanical lithotripsy with EPBD after ES compared with ES alone,<sup>112</sup> 2 randomized, controlled trials reported essentially no differences in outcomes between these techniques.<sup>111,113</sup> Although experience remains relatively limited with EPBD after ES, available high-quality data support consideration of this technique as a strategy for managing large bile duct stones.

**Mechanical lithotripsy.** Mechanical lithotripsy of large CBD stones was first described in 1982<sup>112</sup> and has likely been the most frequently used lithotripsy approach historically, given its minimal expense, ready availability of the required accessories, and lack of the need for cholangioscopy. Classically, mechanical lithotripsy was performed with an external-type (ie, salvage) lithotripter. Integrated through-the-scope mechanical lithotripsy systems have largely replaced external lithotripsy systems, given their ease of use and ability to capture and crush multiple stones in 1 session.<sup>113</sup>

Mechanical lithotripsy for stones not amenable to conventional extraction has a reported success rate of 79% to 92%.<sup>114-117</sup> The most common reason for failure of mechanical lithotripsy is stone impaction in the CBD,<sup>116,117</sup> and very large stones (>2 cm) have also predicted failure.<sup>117</sup> The reported incidence of complications with mechanical lithotripsy ranges from 6% to 13% in large retrospective series,<sup>116,117</sup> with pancreatitis and bleeding representing the most common adverse events. Technical complications, such as basket impaction and traction wire fracture, may complicate mechanical lithotripsy in as many as 4% of cases.<sup>118</sup> Most technical complications can be managed nonoperatively using an external salvage lithotripter or an alternative lithotripsy modality.

**Alternative lithotripsy approaches.** Intraductal shock wave lithotripsy represents an alternative modality for the fragmentation of refractory biliary calculi, allowing subsequent removal. Shock waves may be generated in a fluid medium by a bipolar probe capable of generating a spark in the case of electrohydraulic lithotripsy (EHL) or by pulsed dye laser systems. An ASGE technology status report on biliary and pancreatic lithotripsy devices reviews EHL and laser lithotripsy (LL) in detail.<sup>113</sup> Both EHL and LL are most commonly used with cholangioscopic guidance to allow accurate stone targeting and avoid injury to the

duct wall; however, use of “centering” balloons to allow EHL or LL with fluoroscopic guidance alone has been described.<sup>119,120</sup> Given the relative ease of use of integrated mechanical lithotriptors and the propensity of freely mobile stones to avoid EHL/LL fragmentation, these modalities may be best suited for large impacted stones.

The effectiveness of EHL for stone fragmentation ranges from 82% to 98%,<sup>95,121-123</sup> with the majority of patients requiring a single treatment session, although slightly lower rates of stone clearance (74%-95%).<sup>95,121-124</sup> Outcomes with LL are similar to those seen with EHL; bile duct clearance rates of 88% to 97% have been reported.<sup>125-128</sup> Complications with EHL and LL are reported in 3% to 19%,<sup>120-126,128</sup> with cholangitis and bleeding being the most common adverse events.

#### **Extracorporeal shock wave lithotripsy (ESWL).**

ESWL represents another adjunctive modality in the endoscopic management of difficult CBD stones. Initially used for urolithiasis, ESWL involves the generation of shock waves in a water medium that then travel through the soft tissues of the body (because of their low acoustical impedance). When shock waves arrive at a focus point and impact against a stone, the abrupt change in acoustic impedance generates shearing forces that fragment the stone. Several ESWL systems are commercially available and vary in mechanism for shock-wave generation, focusing, and stone imaging apparatus (generally fluoroscopy, US, or both). Commonly, contrast is instilled via a previously placed nasobiliary catheter to aid in stone visualization, and continuous saline solution irrigation of the bile duct during ESWL has been associated with better outcomes.<sup>129</sup> The newer third-generation lithotriptors do not require an actual water bath and have improved focusing that may reduce collateral tissue damage and patient discomfort, although intravenous sedation is typically used. In most U.S. centers that use biliary ESWL, a collaborative approach with an urologist is typically used.

CBD stone fragmentation rates of 71% to 95% have been reported with ESWL,<sup>121,125,130-132</sup> leading to final ductal clearance rates of 70% to 90%.<sup>121,125,130-135</sup> Most commonly, between 1 and 3 sessions are needed for effective fragmentation, and usually ERC is undertaken within a few days after ESWL to sweep fragments from the duct. Complications have been reported in 10% to 35% of patients undergoing ESWL for choledocholithiasis, including cholangitis, hemobilia, hematuria, and transient arrhythmias.<sup>121,125,129-132</sup>

Three randomized, controlled trials evaluated ESWL compared with EHL<sup>121</sup> or LL.<sup>125,132</sup> In the latter 2 of these trials, LL was associated with a significantly higher rate of ductal clearance than ESWL (83%-97% vs 53%-73%), although no difference in duct clearance rates was seen in the trial comparing EHL and ESWL (74% vs 79%). After crossover to the alternate modality, final duct clearance rates of 91% to 98% were achieved. All 3 trials favored intraductal lithotripsy over ESWL with regard to number of

treatment sessions required, whereas no difference in adverse events was seen.

#### **Hepatolithiasis**

Hepatolithiasis (ie, intrahepatic lithiasis) typically occurs in conjunction with biliary strictures and is seen in the setting of postoperative biliary strictures, primary sclerosing cholangitis, and recurrent pyogenic cholangitis, among other predisposing conditions.<sup>136-138</sup> Ascending cholangitis is a frequent acute complication associated with hepatolithiasis, although chronic complications include secondary biliary cirrhosis, lobar atrophy, and cholangiocarcinoma. Most studies on the management of hepatolithiasis are composed of patients with recurrent pyogenic cholangitis; limited data exist for other etiologies. Management options for hepatolithiasis include per-oral cholangioscopic lithotripsy (POCSL) (ie, cholangioscopy performed at ERC), percutaneous transhepatic cholangioscopic lithotripsy (PTCSL) (ie, cholangioscopy performed percutaneously via a transhepatic tract or T-tube tract) and surgical resection (ie, hepatectomy). Cholangioscopy with intraductal lithotripsy is usually an integral part of nonoperative approaches for hepatolithiasis because intrahepatic stones are difficult to extract in toto at ERC because of associated strictures or, similarly, via a limited-diameter percutaneous tract without previous fragmentation. In a series of POCSL for hepatolithiasis, the rate of complete stone removal was 23 of 36 (64%)<sup>100</sup>; frequent causes of failure were the inability to access the right posteroinferior and left inferolateral segments because of sharp angulations. PTCSL has attained higher rates of complete stone clearance (80%-85%) and thus is used more commonly.<sup>139-141</sup> However, both POCSL and PTCSL are hindered by high rates of stone recurrence (22%-50% on long-term follow-up), with biliary strictures predicting recurrence.<sup>139-141</sup> Hepatectomy has been associated with stone clearance rates greater than 90%<sup>142,143</sup> and fewer recurrences than nonoperative modalities. Hepatectomy should be considered for patients with acceptable functional status and unilateral stone disease, particularly if biliary strictures and/or lobar atrophy are also present.<sup>144</sup> Commonly, a T tube is inserted to facilitate postoperative cholangiography and PTCSL if needed. A multidisciplinary approach including a hepatobiliary surgeon, interventional radiologist, and gastroenterologist is optimal in the management of these challenging patients.

#### **Surgically altered anatomy of the upper gut**

The endoscopic management of choledocholithiasis is frequently more challenging in patients with previous reconstructive surgery of the upper GI tract; ERC in surgically altered anatomy has been reviewed in detail.<sup>102,145,146</sup> Before attempted endoscopic removal of CBD stones, it is prudent to review the surgical report, ensure that required endoscopes and devices are available, and consider and discuss nonendoscopic alternatives with the patient. Se-

lected postsurgical anatomic states and their impact on CBD stone management are reviewed.

**Billroth II.** Billroth II gastrojejunal reconstructions have been used frequently in the setting of antrectomy for benign or neoplastic gastric disease. Because of the retrograde direction of the endoscopic approach, the orientation of the major papilla is rotated 180 degrees compared with a typical antegrade approach. A duodenoscope or therapeutic gastroscope can traverse the afferent limb and reach the major papilla, and cannulation success rates approximating 90% have been reported with both endoscopes.<sup>101,147</sup> Given the papillary orientation, ES is performed using a specialty papillotome, rotatable papillotome, or, more commonly, using a needle-knife after placement of a biliary stent. EPBD is also an option in these patients to facilitate stone removal; it is technically easier than sphincterotomy and was as effective in a randomized, controlled trial of 34 patients with bile duct stones and Billroth II anatomy, with no difference in complications.<sup>68</sup> Overall, high rates of success (85%-92%) have been reported for endoscopic treatment of CBD stones in Billroth II patients.<sup>68,147,148</sup> However, postsphincterotomy bleeding (reported in as many as 17% of patients<sup>68</sup>) and luminal perforations (reported in as many as 5% of patients<sup>149</sup>) occur more frequently during ERC in Billroth II patients than in patients with native anatomy.<sup>68,149-151</sup>

**Roux-en-Y reconstructions.** In patients with Roux-en-Y gastrojejunostomy (RYGJ) or Roux-en-Y hepaticojejunostomy (RYHJ) anatomy, a duodenoscope typically lacks the length and maneuverability needed to navigate the Roux limb to reach the papilla or hepaticojejunostomy.<sup>148</sup> As such, pediatric colonoscopes and standard enteroscopes,<sup>152-154</sup> and, more recently, balloon-assisted enteroscopes<sup>155-160</sup> have been used with varying success (62%-100%) for reaching the papilla or hepaticojejunostomy. Biliary cannulation with a forward-viewing colonoscope or enteroscope can be challenging; most operators have reported native papilla cannulation rates of 70% to 80% in this setting, if the papilla can be reached.<sup>155,161,155</sup> Stone removal techniques are similar to those used in Billroth II anatomy, and these patients also share an increased risk (as many as 5%) of perforation.<sup>156</sup>

Patients who have undergone Roux-en-Y gastric bypass (RYGB), which differs from RYGJ and RYHJ reconstructions in 2 regards that are clinically relevant to the performance of biliary endoscopy. First, the creation of the Roux jejunostomy is frequently a greater distance from the stomach, resulting in both longer alimentary (Roux) and biliopancreatic limbs and thus potentially more difficulty in reaching the biliary orifice. However, data are mixed as to whether RYGB anatomy is associated with a lower rate of successful access to the biliary orifice compared with RYGJ or RYHJ when balloon-assisted enteroscopy is used.<sup>155,159</sup>

Second, the intact antroduodenal pathway to the biliary tree makes transgastric endoscopic approaches possible in

RYGB patients, which are not options in RYGJ and RYHJ. One option is the creation of a surgical or radiologic gastrostomy into the excluded stomach and subsequent access and dilation of the gastrostomy tract after allowing 3 to 4 weeks for tract maturation.<sup>162,163</sup> Alternatively, laparoscopy-assisted ERCP involves the creation of a laparoscopic gastrotomy and intraoperative passage of a duodenoscope via the newly created gastrotomy. This method has been associated with high rates (90%-100%) of therapeutic success, including CBD stone removal.<sup>164-166</sup> A gastrostomy tube can be placed after ERCP if repeat intervention is anticipated. Complication rates of as high as 13% have been reported with this technique, including perforation/leak at the gastrotomy site and wound infection.<sup>170</sup>

### Mirizzi syndrome

Mirizzi syndrome refers to obstruction of the common hepatic duct by a gallstone impacted in the cystic duct or gallbladder neck. It is an uncommon complication of gallstone disease, reported in approximately 0.3% of large series of cholecystectomies.<sup>167,168</sup> Historically, the role of ERC was to diagnose Mirizzi syndrome and relieve biliary obstruction via stenting before definitive surgical management. However, case series also describe successful endoscopic stone removal in Mirizzi syndrome, usually after some form of intraductal lithotripsy or ESWL, both pre- and postoperatively.<sup>103,169,170</sup> Some elderly patients with poor functional status and patients without additional gallbladder stones have been managed with endoscopic stone removal alone.<sup>103,169,170</sup>

## NONENDOSCOPIC MODALITIES FOR BILIARY STONE MANAGEMENT

### Surgical management

IOC and open CBD exploration for stone removal were frequently performed before the advent of laparoscopic cholecystectomy. In this setting, there was no advantage of preoperative ERC over 1-stage surgical management in randomized, controlled trials.<sup>171</sup> Laparoscopic cholecystectomy has now supplanted open cholecystectomy because of attenuated morbidity and shorter hospital stays. Laparoscopic IOC and transcystic stone removal or removal via laparoscopic choledochotomy (henceforth collectively termed laparoscopic CBD exploration [LCBDE]) are also reasonable treatment options in patients with known or highly suspected choledocholithiasis undergoing cholecystectomy. As an alternative, laparoscopic transcystic antegrade placement of a transpapillary biliary stent to ensure access at postoperative ERC has been described.<sup>172</sup>

Randomized, controlled trials have compared LCBDE at laparoscopic cholecystectomy with both preoperative ERC followed by laparoscopic cholecystectomy for patients at high risk of choledocholithiasis<sup>173-175</sup> as well as postoper-

ative ERC for patients with a positive IOC.<sup>176,177</sup> In general, the primary ductal clearance rates, morbidity, and mortality are similar in ERC and LCBDE in these trials.<sup>174-177</sup> Some trials report a shorter hospital stay for patients treated with LCBDE,<sup>173,177,173</sup> and, not surprisingly, a need for fewer total procedures for those in the 1-step arm than those treated in 2 stages.<sup>175,178,175</sup>

Although LCBDE is an attractive concept for CBD stone management given its similar efficacy and improved efficiency compared with ERC, its adoption has not been widespread.<sup>179-182</sup> Thus, LCBDE is a first-line strategy for choledocholithiasis management, but is limited to centers where appropriate expertise is available.

### Percutaneous management

At present, percutaneous management of biliary stones is most commonly used in the setting of hepatolithiasis. However, percutaneous techniques have also been used for extrahepatic biliary stones via a T-tube sinus tract or percutaneous transhepatic tract.<sup>183-186</sup> High rates of successful duct clearance (90%-100%) using a variety of techniques have consistently been reported with percutaneous approaches.<sup>183-191</sup> However, severe bleeding events have been reported in as many as 14% of patients with percutaneous transhepatic approaches, with mortality as high as 8%.<sup>184,188</sup> Given the logistical complexity (percutaneous tracts take time to mature), incidence of severe complications, and available alternatives, percutaneous techniques for managing extrahepatic bile duct stones are not recommended as a first-line strategy. However, removal of small stones via a mature T-tube sinus tract represents a potential exception because excellent results have been achieved in experienced hands.<sup>183</sup>

### Dissolution of CBD stones

**Bile acids.** Data for oral administration of bile salts as a stand-alone therapy for choledocholithiasis are limited and not favorable<sup>192</sup>; this approach is not recommended. Nonrandomized studies of ursodeoxycholic acid (UDCA) as an adjunct to biliary stenting in patients with bile duct stones refractory to endoscopic removal suggested that treatment with 600 mg/day of UDCA for 6 to 9 months is associated with a reduction in stone size and CBD diameter and facilitates subsequent endoscopic duct clearance in 90% to 93% of patients.<sup>193,194</sup> However, a randomized, controlled trial did not support these results. Forty-one patients with large CBD stones in whom endoscopic extraction failed all had a 10F biliary stent placed and were then randomized to 750 mg UDCA/day or placebo for 6 months.<sup>195</sup> At follow-up, there was no difference in stone size or final ductal clearance rates between the 2 groups.

**Topical solvents.** Topical solvents including mono-octanoin and methyl tert-butyl ether were also evaluated in the 1980s for more rapid dissolution of retained cholesterol stones in the CBD. Although effective in 55% to 90% of patients for achieving complete or partial dissolution

facilitating endoscopic removal, hepatic and duodenal toxicity of these agents (particularly of methyl tert-butyl ether), frequent adverse effects (eg, vomiting, diarrhea, pain), and cumbersome treatment protocols severely limit the application of these techniques.<sup>196-199</sup>

### MANAGEMENT OF RECURRENT STONE FORMATION

Despite apparently complete clearance of bile duct stones at ERC, recurrent CBD stones developed in 3% to 15% of patients in series with long-term (>5 years) follow-up.<sup>200-205</sup> Other than gallbladder in situ, risk factors for stone recurrence generally relate to conditions predisposing to bile stasis, including bile duct dilation greater than 15 mm,<sup>203,204</sup> and anatomic lesions that may impede bile flow (eg, periampullary diverticuli,<sup>203,206</sup> angulation of the CBD,<sup>207</sup> and biliary strictures or papillary stenosis<sup>208</sup>). It should be noted that the vast majority of recurrent or de novo CBD stones are brown pigment stones<sup>204</sup> whose formation is dependent on bacteria (infected bile is nearly ubiquitous in brown pigment stones) and whose composition and pathogenesis differ significantly from those of other types of stones.<sup>209</sup> Fortunately, recurrent CBD stones can be managed at ERC with a high rate of success.<sup>204,210</sup>

In patients with documented CBD stone recurrence, biliary stasis and its predisposing factors may be difficult to definitively correct, and alternative management strategies can be considered. In a small series of 13 patients with 2 or more documented recurrences of CBD stones, a decision to perform annual surveillance ERC for duct sweeping was associated with a reduction in the frequency of ascending cholangitis.<sup>211</sup> The role of UDCA was evaluated in a small trial of 46 patients status post endoscopic clearance of bile duct stones. One of 22 patients who received UDCA 500 mg/day had CBD stone recurrence during approximately 18 months of follow-up compared with 4 of 26 patients receiving placebo.<sup>212</sup> However, data on UDCA in this role remain very limited, and given the different pathogenesis of brown pigment stones compared with cholesterol gallbladder stones, the biological plausibility is not as well established in this setting. Surgical choledochoduodenostomy or related biliary-enteric anastomoses have also been described in the management of recurrent CBD stones.<sup>213-215</sup> However, choledochoduodenostomy has been associated with as much as 5% in-hospital mortality,<sup>216</sup> and a 10% to 28% adverse event rate, including cholangitis, sump syndrome, bile leak, and wound infection.<sup>212,217-219</sup> As such, the role of choledochoduodenostomy is limited to patients with recurrent CBD stones refractory to nonsurgical management.<sup>46</sup>

### RECOMMENDATIONS

1. We recommend that CBD stones should be removed if detected unless significant mitigating clinical circumstances are present. ⊕⊕⊕○

2. The optimal timing of endoscopic stone management depends on the clinical scenario. We recommend that urgent ERC is indicated for stones associated with severe acute cholangitis that is not responding to medical treatment. ⊕⊕
3. In the setting of symptomatic cholelithiasis, we suggest that preoperative ERC for patients with a high likelihood of choledocholithiasis or intraoperative or postoperative ERC for patients with a positive IOC are all valid and comparable approaches. ⊕⊕⊕⊕
4. If preoperative ERC is undertaken for choledocholithiasis, we recommend subsequent cholecystectomy in most cases. ⊕⊕⊕⊕ We recommend that cholecystectomy be performed within 2 weeks because longer delays have been associated with increased morbidity from recurrent biliary events. ⊕⊕⊕⊕
5. We suggest that antibiotic prophylaxis is unnecessary in the majority of patients with suspected choledocholithiasis, unless cholangitis or immunosuppression is present or biliary drainage is predicted to be incomplete. ⊕⊕⊕⊕
6. We recommend against routine use of primary EPBD given the reported risks of severe pancreatitis, although it may be considered in select clinical circumstances that increase the risk or difficulty of ES. ⊕⊕⊕⊕
7. We recommend placement of a plastic biliary endoprosthesis to ensure adequate drainage in cases of incomplete stone extraction or severe acute cholangitis. ⊕⊕⊕⊕
8. We recommend against the use of plastic biliary stents as a sole therapy for CBD stones refractory to initial endoscopic extraction, given the high frequency of late biliary complications associated with this strategy. ⊕⊕⊕⊕
9. For large, nonimpacted CBD stones refractory to initial extraction efforts, we suggest that mechanical lithotripsy or EPBD after ES be considered as next steps, given their effectiveness, ease of use, and acceptable safety profiles. ⊕⊕⊕⊕
10. We suggest that in patients with large and/or impacted calculi refractory to mechanical lithotripsy, intraductal lithotripsy (EHL or LL) is preferred over ESWL, given the superior rates of ductal clearance. ⊕⊕⊕⊕
11. Given the increased rate of complications and lower success rate of endoscopic management of CBD stones in patients who have undergone Billroth II or Roux-en-Y reconstructions, we suggest that these patients be referred to biliary centers of excellence. ⊕⊕⊕⊕
12. We recommend that LCBDE is an alternative to ERC as a first-line strategy for CBD stone removal in the setting of symptomatic cholelithiasis in centers where surgical expertise is available. ⊕⊕⊕⊕
13. We recommend against primary percutaneous transhepatic management of CBD stones in patients with native anatomy, given that more expeditious alternatives with similar or better risk profiles exist (eg, ERC, LCBDE). ⊕⊕⊕⊕
14. We suggest that UDCA may be considered as an adjunct to biliary stenting in the management of difficult stones. ⊕⊕⊕⊕
15. We recommend that recurrent CBD stones may be effectively managed with repeat ERC. ⊕⊕⊕⊕ Limited data guide further decision making in these patients, and the use of UDCA, surveillance ERC, or a biliary-enteric bypass must be individualized.

## DISCLOSURE

*The following authors disclosed financial relationships relevant to this publication: Dr. Jain: research support, Barrx; Dr. Fanelli: royalties, Cook Surgical, honoraria, Ethicon; consultant, RTI Biology, New Wave Surgical Corp, owner/governor; Dr. Evans: consultant, Cook Medical; Dr. Decker: consultant, Facet Biotechnology. The other authors disclosed no financial relationships relevant to this publication.*

*Abbreviations: ASGE, American Society for Gastrointestinal Endoscopy; CBD, common bile duct; EHL, electrohydraulic lithotripsy; EPBD, endoscopic papillary balloon dilation; ERC, endoscopic retrograde cholangiography; ES, endoscopic sphincterotomy; ESWL, extracorporeal shock wave lithotripsy; IOC, intraoperative cholangiography; LCBDE, laparoscopic common bile duct exploration; LL, laser lithotripsy; POCSL, peroral cholangioscopic lithotripsy; PTC, percutaneous transhepatic cholangiography; PTCSL, percutaneous transhepatic cholangioscopic lithotripsy; RYGB, Roux-en-Y gastric bypass; RYJ, Roux-en-Y gastrojejunostomy; RYHJ, Roux-en-Y hepaticojejunostomy; UDCA, ursodeoxycholic acid.*

## REFERENCES

1. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-6.
2. Everhart JE, Khare M, Hill M, et al. Prevalence and ethnic differences in gallbladder disease in the United States. *Gastroenterology* 1999;117:632-9.
3. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States I: overall and upper gastrointestinal diseases. *Gastroenterology* 2009;136:376-86.
4. Hunter JG. Laparoscopic transcystic bile duct exploration. *Am J Surg* 1992;163:53-6.
5. Robinson BL, Donohue JH, Gunes S, et al. Selective operative cholangiography: appropriate management for laparoscopic cholecystectomy. *Arch Surg* 1995;130:625-30.
6. Petelin JB. Laparoscopic common bile duct exploration. *Surg Endosc* 2003;17:1705-15.
7. O'Neill CJ, Gillies DM, Gani JS. Choledocholithiasis: overdiagnosed endoscopically and undertreated laparoscopically. *ANZ J Surg* 2008;78:487-91.
8. Chang L, Lo SK, Stabile BE, et al. Gallstone pancreatitis: a prospective study on the incidence of cholangitis and clinical predictors of retained common bile duct stones. *Am J Gastroenterol* 1998;93:527-31.
9. Chak A, Hawes RH, Cooper GS, et al. Prospective assessment of the utility of EUS in the evaluation of gallstone pancreatitis. *Gastrointest Endosc* 1999;49:599-604.



10. Liu CL, Lo CM, Chan JKF, et al. Detection of choledocholithiasis by EUS in acute pancreatitis: a prospective evaluation in 100 consecutive patients. *Gastrointest Endosc* 2001;54:325-30.
11. Cohen ME, Slezak L, Wells CK, et al. Prediction of bile duct stones and complications in gallstone pancreatitis using early laboratory trends. *Am J Gastroenterol* 2001;96:3305-11.
12. ASGE Standards of Practice Committee: Maple JT, Ben-Menachem T, Anderson MA, et al. The role of endoscopy in the evaluation of suspected choledocholithiasis. *Gastrointest Endosc* 2010;71:1-9.
13. Oria A, Alvarez J, Chiappetta L, et al. Risk factors for acute pancreatitis in patients with migrating gallstones. *Arch Surg* 1989;124:1295-6.
14. Frossard JL, Hadengue A, Amouyal G, et al. Choledocholithiasis: a prospective study of spontaneous bile duct stone migration. *Gastrointest Endosc* 2000;51:175-9.
15. Lee SH, Hwang JH, Yang KY, et al. Does endoscopic sphincterotomy reduce the recurrence rate of cholangitis in patients with cholangitis and suspected of a common bile duct stone not detected at ERCP? *Gastrointest Endosc* 2008;67:51-7.
16. Collins C, Maguire D, Ireland A, et al. A prospective study of common bile duct calculi in patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited. *Ann Surg* 2004;239:28-33.
17. Williams EJ, Green J, Beckingham I, et al; British Society of Gastroenterology. Guidelines on the management of common bile duct stones (CBDs). *Gut* 2008;57:1004-21.
18. Paul A, Millat B, Holthausen U, et al. Diagnosis and treatment of common bile duct stones: results of a consensus development conference. *Surg Endosc* 1998;12:856-64.
19. Demling L, Koch H, Classen M. Endoscopic papillotomy and removal of gallstones: animal experiments and first clinical results [in German]. *Dtsch Med Wochenschr* 1974;99:2255-7.
20. Cotton PB. Non-operative removal of bile duct stones by duodenoscopic sphincterotomy. *Br J Surg* 1980;67:1-5.
21. Colton JB, Curran CC. Quality indicators, including complications, of ERCP in a community setting: a prospective study. *Gastrointest Endosc* 2009;70:468-70.
22. Mo LR, Chang KK, Wang CH, et al. Preoperative endoscopic sphincterotomy in the treatment of patients with cholecystocholedocholithiasis. *J Hepatobiliary Pancreat Surg* 2002;9:191-5.
23. Bergman JJ, Rauws EAJ, Fockens P, et al. Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bile duct stones. *Lancet* 1997;349:1114-5.
24. Granke K, Jordan FT, Mazzeo RJ, et al. Endoscopic papillotomy: impact on community hospital treatment of common duct stones. *Am Surg* 1988;54:347-51.
25. Ponchon T, Bory R, Chavaillon A, et al. Biliary lithiasis: combined endoscopic and surgical treatment. *Endoscopy* 1989;21:15-8.
26. Elfant AB, Bourke MJ, Alhalel R, et al. A prospective study of the safety of endoscopic therapy for choledocholithiasis in an outpatient population. *Am J Gastroenterol* 1996;91:1499-502.
27. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. *N Engl J Med* 1996;335:909-18.
28. Cotton PB, Geenen JE, Sherman S, et al. Endoscopic sphincterotomy for stones by experts is safe, even in younger patients with normal ducts. *Ann Surg* 1998;227:201-4.
29. Mayumi T, Takada T, Kawarada Y, et al. Results of the Tokyo Consensus Meeting Tokyo Guidelines. *J Hepatobiliary Pancreat Surg* 2007;14:114-21.
30. Bornman PC, van Beljon JI, Krige JEJ. Management of cholangitis. *J Hepatobiliary Pancreat Surg* 2003;10:406-14.
31. Boender J, Nix GA, de Ridder MA, et al. Endoscopic sphincterotomy and biliary drainage in patients with cholangitis due to common bile duct stones. *Am J Gastroenterol* 1995;90:233-8.
32. Acosta JM, Katkhouda N, Debian KA, et al. Early ductal decompression versus conservative management for gallstone pancreatitis with ampullary obstruction: a prospective randomized clinical trial. *Ann Surg* 2006;243:33-40.
33. Neoptolemos JP, Carr-Locke DL, London NJ, et al. Controlled trial of urgent endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy versus conservative treatment for acute pancreatitis due to gallstones. *Lancet* 1988;2:979-83.
34. Fan ST, Lai ECS, Mok FPT, et al. Early treatment of acute biliary pancreatitis by endoscopic papillotomy. *N Engl J Med* 1993;328:228-32.
35. Nowak A, Nowakowska-Dulawa E, Marek T, et al. Final results of the prospective, randomized, controlled study on endoscopic sphincterotomy versus conventional management in acute biliary pancreatitis [abstract]. *Gastroenterology* 1995;108(Suppl):A380.
36. Oria A, Cimmino D, Ocampo C, et al. Early endoscopic intervention versus early conservative management in patients with acute gallstone pancreatitis and biliopancreatic obstruction: a randomized clinical trial. *Ann Surg* 2007;245:10-7.
37. Folsch UR, Nitsche R, Ludtke R, et al. Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis; the German Study Group on acute biliary pancreatitis. *N Engl J Med* 1997;336:237-42.
38. Katz D, Nikfarjam M, Sfakiotaki A, et al. Selective endoscopic cholangiography for the detection of common bile duct stones in patients with cholelithiasis. *Endoscopy* 2004;36:1045-9.
39. Byrne MF, McLoughlin MT, Mitchell RM, et al. For patients with predicted low risk for choledocholithiasis undergoing laparoscopic cholecystectomy, selective intraoperative cholangiography and postoperative endoscopic retrograde cholangiopancreatography is an effective strategy to limit unnecessary procedures. *Surg Endosc* 2009;23:1933-7.
40. Wright BE, Freeman ML, Cumming JK, et al. Current management of common bile duct stones: Is there a role for laparoscopic cholecystectomy and intraoperative endoscopic retrograde cholangiopancreatography as a single-stage procedure? *Surgery* 2002;132:729-37.
41. Tricarico A, Cione G, Sozio M, et al. Endolaparoscopic rendezvous treatment: a satisfying therapeutic choice for cholecystocholedocholithiasis. *Surg Endosc* 2002;16:585-8.
42. Nathanson LK, O'Rourke NA, Martin IJ, et al. Postoperative ERCP versus laparoscopic choledochotomy for clearance of selected bile duct calculi. *Ann Surg* 2005;242:188-92.
43. Ammori BJ, Birbas K, Davides D, et al. Routine vs "on demand" postoperative ERCP for small bile duct calculi detected at intraoperative cholangiography. Clinical evaluation and cost analysis. *Surg Endosc* 2000;14:1123-6.
44. Chang L, Lo S, Stabile BE, et al. Preoperative versus postoperative endoscopic retrograde cholangiopancreatography in mild to moderate gallstone pancreatitis: a prospective randomized trial. *Ann Surg* 2000;231:82-7.
45. Pierce RA, Jonnalagadda S, Spitler JA, et al. Incidence of residual choledocholithiasis detected by intraoperative cholangiography at the time of laparoscopic cholecystectomy in patients having undergone preoperative ERCP. *Surg Endosc* 2008;22:2365-72.
46. Chiappetta Porras LT, Nápoli ED, Canullán CM, et al. Laparoscopic bile duct reexploration for retained duct stones. *J Gastrointest Surg* 2008;12:1518-20.
47. De Vries A, Donkervoort SC, van Geloven AA, et al. Conversion rate of laparoscopic cholecystectomy after endoscopic retrograde cholangiography in the treatment of choledocholithiasis: does the time interval matter? *Surg Endosc* 2005;19:996-1001.
48. Schiphorst AH, Besselink MG, Boerma D, et al. Timing of cholecystectomy after endoscopic sphincterotomy for common bile duct stones. *Surg Endosc* 2008;22:2046-50.
49. Ito K, Ito H, Whang EE. Timing of cholecystectomy for biliary pancreatitis: do the data support current guidelines? *J Gastrointest Surg* 2008;12:2164-70.
50. Chiang DT, Thompson G. Management of acute gallstone pancreatitis: so the story continues. *ANZ J Surg* 2008;78:52-4.
51. Reinders JS, Goud A, Timmer R, et al. Early laparoscopic cholecystectomy improves outcomes after endoscopic sphincterotomy for choledochocystolithiasis. *Gastroenterology* 2010;138:2315-20.

52. Escourrou J, Cordova JA, Lazorthes F, et al. Early and late complications after endoscopic sphincterotomy for biliary lithiasis with and without the gall bladder 'in situ'. *Gut* 1984;25:598-602.
53. McAlister VC, Davenport E, Renouf E. Cholecystectomy deferral in patients with endoscopic sphincterotomy. *Cochrane Database Syst Rev* 2007;4:CD006233.
54. ASGE Standards of Practice Committee: Banerjee S, Shen B, Baron TH, et al. Antibiotic prophylaxis for GI endoscopy. *Gastrointest Endosc* 2008;67:791-8.
55. Gardner TB, Baron TH. Optimizing cholangiography when performing endoscopic retrograde cholangiopancreatography. *Clin Gastroenterol Hepatol* 2008;6:734-40.
56. Prat F, Amouyal G, Amouyal P, et al. Prospective controlled study of endoscopic ultrasonography and endoscopic retrograde cholangiography in patients with suspected common bile duct lithiasis. *Lancet* 1996;347:75-9.
57. Tseng LJ, Jao YT, Mo LR, et al. Over-the-wire US catheter probe as an adjunct to ERCP in the detection of choledocholithiasis. *Gastrointest Endosc* 2001;54:720-3.
58. Siddique I, Mohan K, Khajah A, et al. Sphincterotomy in patients with gallstones, elevated LFTs, and a normal CBD on ERCP. *Hepatogastroenterology* 2003;50:1242-5.
59. Lee SH, Hwang JH, Yang KY, et al. Does endoscopic sphincterotomy reduce the recurrence rate of cholangitis in patients with cholangitis and suspected of a common bile duct stone not detected by ERCP? *Gastrointest Endosc* 2008;67:51-7.
60. Rocca R, De Angelis C, Castellino F, et al. EUS diagnosis and simultaneous endoscopic retrograde cholangiography treatment of common bile duct stones by using an oblique-viewing echoendoscope. *Gastrointest Endosc* 2006;63:479-84.
61. Artifon ELA, Kumar A, Eloubeidi MA, et al. Prospective randomized trial of EUS versus ERCP-guided common bile duct stone removal: an interim report (with video). *Gastrointest Endosc* 2009;69:238-43.
62. May GR, Cotton PB, Edmunds SE, et al. Removal of stones from the bile duct at ERCP without sphincterotomy. *Gastrointest Endosc* 1993;39:749-54.
63. DiSario JA, Freeman ML, Bjorkman DJ, et al. Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. *Gastroenterology* 2004;127:1291-9.
64. Baron TH, Harewood GC. Endoscopic balloon dilation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: a metaanalysis of randomized controlled trials. *Am J Gastroenterol* 2004;99:1455-60.
65. Weinberg BM, Shindy W, Lo S. Endoscopic balloon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stones. *Cochrane Database Syst Rev* 2006;18:CD004890.
66. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. *Gastrointest Endosc* 2001;54:425-34.
67. Kawabe T, Komatsu Y, Tada M, et al. Endoscopic papillary balloon dilation in cirrhotic patients: removal of common bile duct stones without sphincterotomy. *Endoscopy* 1996;28:694-8.
68. Bergman JJ, van Berkel AM, Bruno MJ, et al. A randomized trial of endoscopic balloon dilation and endoscopic sphincterotomy for removal of bile duct stones in patients with a prior Billroth II gastrectomy. *Gastrointest Endosc* 2001;53:19-26.
69. Liao WC, Huang SP, Wu MS, et al. Comparison of endoscopic papillary balloon dilatation and sphincterotomy for lithotripsy in difficult sphincterotomy. *J Clin Gastroenterol* 2008;42:295-9.
70. Elta GH, Barnett JL, Wille RT, et al. Pure cut electrocautery current for sphincterotomy causes less post-procedure pancreatitis than blended current. *Gastrointest Endosc* 1998;47:149-53.
71. Stefanidis G, Karamanolis G, Viazis N, et al. A comparative study of postendoscopic sphincterotomy complications with various types of electrocautery current in patients with choledocholithiasis. *Gastrointest Endosc* 2003;57:192-7.
72. Verma D, Kapadia A, Adler DG. Pure versus mixed electrocautery current for endoscopic biliary sphincterotomy: a meta-analysis of adverse outcomes. *Gastrointest Endosc* 2007;66:283-90.
73. Leung JW, Banez VP, Chung SC. Precut (needle knife) papillotomy for impacted common bile duct stone at the ampulla. *Am J Gastroenterol* 1990;85:991-3.
74. ASGE Technology Committee, Adler DG, Conway JD, Farraye FA, et al. Biliary and pancreatic stone extraction devices. *Gastrointest Endosc* 2009;70:603-9.
75. Tytgat GN, Bartelsman J, Huijbregtse K, et al. Common duct complications of choledocholithiasis revealed by ERCP. *Gastrointest Endosc* 1979;25:63-6.
76. Stave R, Osnes M. Endoscopic gallstone extraction following hydrostatic balloon dilatation of a stricture in the common bile duct. *Endoscopy* 1985;17:159-60.
77. Binmoeller KF, Schafer TW. Endoscopic management of bile duct stones. *J Clin Gastroenterol* 2001;32:106-18.
78. Sharma BC, Kumar R, Agarwal N, et al. Endoscopic biliary drainage by nasobiliary drain or by stent placement in patients with acute cholangitis. *Endoscopy* 2005;37:439-43.
79. Lee DW, Chan AC, Lam YH, et al. Biliary decompression by nasobiliary catheter or biliary stent in acute suppurative cholangitis: a prospective randomized trial. *Gastrointest Endosc* 2002;56:361-5.
80. Park SY, Park CH, Cho SB, et al. The safety and effectiveness of endoscopic biliary decompression by plastic stent placement in acute suppurative cholangitis compared with nasobiliary drainage. *Gastrointest Endosc* 2008;68:1076-80.
81. Jain SK, Stein R, Bhuvra M, et al. Pigtail stents: an alternative in the treatment of difficult bile duct stones. *Gastrointest Endosc* 2000;52:490-3.
82. Chan AC, Ng EK, Chung SC, et al. Common bile duct stones become smaller after endoscopic biliary stenting. *Endoscopy* 1998;30:356-9.
83. Katsinelos P, Galanis I, Pilpilidis I, et al. The effect of indwelling endoprosthesis on stone size or fragmentation after long-term treatment with biliary stenting for large stones. *Surg Endosc* 2003;17:1552-5.
84. Bergman JJ, Rauws EA, Tijssen JG, et al. Biliary endoprosthesis in elderly patients with endoscopically irretrievable common bile duct stones: report on 117 patients. *Gastrointest Endosc* 1995;42:195-201.
85. Chopra KB, Peters RA, O'Toole PA, et al. Randomised study of endoscopic biliary endoprosthesis versus duct clearance for bile duct stones in high-risk patients. *Lancet* 1996;348:791-3.
86. De Palma GD, Galloro G, Siciliano S, et al. Endoscopic stenting for definitive treatment of irretrievable common bile duct calculi. A long-term follow-up study of 49 patients. *Hepatogastroenterology* 2001;48:56-8.
87. Hui CK, Lai KC, Ng M, et al. Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy. *Aliment Pharmacol Ther* 2003;17:289-96.
88. Ramirez FC, Dennert B, Sanowski RA. Success of repeat ERCP by the same endoscopist. *Gastrointest Endosc* 1999;47:368-71.
89. Kumar S, Sherman S, Hawes RH, et al. Success and yield of 2nd attempt ERCP. *Gastrointest Endosc* 1995;41:445-7.
90. Shorvon PJ, Cotton PB, Mason RR, et al. Percutaneous transhepatic assistance for duodenoscopic sphincterotomy. *Gut* 1985;26:1373-6.
91. Dowsett JF, Vaira D, Hatfield AR, et al. Endoscopic biliary therapy using the combined endoscopic and percutaneous technique. *Gastroenterology* 1989;96:1180-6.
92. van der Velden JJ, Berger MY, Bonjer HJ, et al. Percutaneous treatment of bile duct stones in patients treated unsuccessfully with endoscopic retrograde procedures. *Gastrointest Endosc* 2000;51:418-22.
93. Kim YS, Gupta K, Mallery S, et al. Endoscopic ultrasound rendezvous for bile duct access using a transduodenal approach: cumulative experience at a single center. A case series. *Endoscopy* 2010;42:496-502.
94. Tzovaras G, Baloyiannis I, Kapsoritakis A, et al. Laparoendoscopic rendezvous: an effective alternative to a failed preoperative ERCP in patients with cholecystocholedocholithiasis. *Surg Endosc* 2010;24:2603-6.

95. Binmoeller KF, Bruckner M, Thonke F, et al. Treatment of difficult bile duct stones using mechanical, electrohydraulic and extracorporeal shock wave lithotripsy. *Endoscopy* 1993;25:201-6.
96. Schutz SM, Abbott RM. Grading ERCPs by degree of difficulty: a new concept to produce more meaningful outcome data. *Gastrointest Endosc* 2000;51:535-9.
97. Chutkan RK, Ahmad AS, Cohen J, et al: ERCP Core Curriculum prepared by ASGE Training Committee. ERCP core curriculum. *Gastrointest Endosc* 2006;63:361-76.
98. Lauri A, Horton RC, Davidson BR, et al. Endoscopic extraction of bile duct stones: management related to stone size. *Gut* 1993;34:1718-21.
99. Zoepf T, Zoepf DS, Arnold JC, et al. The relationship between juxta papillary duodenal diverticula and disorders of the biliopancreatic system: analysis of 350 patients. *Gastrointest Endosc* 2001;54:56-61.
100. Kennedy RH, Thompson MH. Are duodenal diverticula associated with choledocholithiasis? *Gut* 1988;29:1003-6.
101. Tyagi P, Sharma P, Sharma BC, et al. Periampullary diverticula and technical success of endoscopic retrograde cholangiopancreatography. *Surg Endosc* 2009;23:1342-5.
102. Boix J, Lorenzo-Zúñiga V, Añaños F, et al. Impact of periampullary duodenal diverticula at endoscopic retrograde cholangiopancreatography: a proposed classification of periampullary duodenal diverticula. *Surg Laparosc Endosc Percutan Tech* 2006;16:208-11.
103. Chang-Chien CS. Do juxta papillary diverticula of the duodenum interfere with cannulation at endoscopic retrograde cholangiopancreatography? A prospective study. *Gastrointest Endosc* 1987;33:298-300.
104. Kim HJ, Choi HS, Park JH, et al. Factors influencing the technical difficulty of endoscopic clearance of bile duct stones. *Gastrointest Endosc* 2007;66:1154-60.
105. Ersoz G, Tekesin O, Ozutemiz AO, et al. Biliary sphincterotomy plus dilation with a large balloon for bile duct stones that are difficult to extract. *Gastrointest Endosc* 2003;57:156-9.
106. Heo JH, Kang DH, Jung HJ, et al. Endoscopic sphincterotomy plus large-balloon dilation versus endoscopic sphincterotomy for removal of bile-duct stones. *Gastrointest Endosc* 2007;66:720-6.
107. Itoi T, Itokawa F, Sofuni A, et al. Endoscopic sphincterotomy combined with large balloon dilation can reduce the procedure time and fluoroscopy time for removal of large bile duct stones. *Am J Gastroenterol* 2009;104:560-5.
108. Kim HG, Cheon YK, Cho YD, et al. Small sphincterotomy combined with endoscopic papillary large balloon dilation versus sphincterotomy. *World J Gastroenterol* 2009;14:4298-304.
109. Minami A, Hirose S, Nomoto T, et al. Small sphincterotomy combined with papillary dilation with large balloon permits retrieval of large stones without mechanical lithotripsy. *World J Gastroenterol* 2007;13: 2179-82.
110. Maydeo A, Bhandari S. Balloon sphincteroplasty for removing difficult bile duct stones. *Endoscopy* 2007;39:958-61.
111. Draganov PV, Evans W, Fazel A, et al. Large size balloon dilation of the ampulla after biliary sphincterotomy can facilitate endoscopic extraction of difficult bile duct stones. *J Clin Gastroenterol* 2009;43:782-6.
112. Riemann JF, Seuberth K, Demling L. Clinical application of a new mechanical lithotripter for smashing common bile duct stones. *Endoscopy* 1982;14:226-30.
113. DiSario J, Chuttani R, Croffie J, et al. Biliary and pancreatic lithotripsy devices. *Gastrointest Endosc* 2007;65:750-6.
114. Shaw MJ, Mackie RD, Moore JP, et al. Results of a multicenter trial using a mechanical lithotripter for the treatment of large bile duct stones. *Am J Gastroenterol* 1993;88:730-3.
115. Vij JC, Jain M, Rawal KK, et al. Endoscopic management of large bile duct stones by mechanical lithotripsy. *Indian J Gastroenterol* 1995;14: 122-3.
116. Garg PK, Tandon RK, Ahuja V, et al. Predictors of unsuccessful mechanical lithotripsy and endoscopic clearance of large bile duct stones. *Gastrointest Endosc* 2004;59:601-5.
117. Chang WH, Chu CH, Wang TE, et al. Outcome of simple use of mechanical lithotripsy of difficult common bile duct stones. *World J Gastroenterol* 2005;11:593-6.
118. Thomas M, Howell DA, Carr-Locke D, et al. Mechanical lithotripsy of pancreatic and biliary stones: complications and available treatment options collected from expert centers. *Am J Gastroenterol* 2007;102: 1896-902.
119. Moon JH, Cha SW, Ryu CB, et al. Endoscopic treatment of retained bile-duct stones by using a balloon catheter for electrohydraulic lithotripsy without cholangioscopy. *Gastrointest Endosc* 2004;60:562-6.
120. Kim TH, Oh HJ, Choi CS, et al. Clinical usefulness of transpapillary removal of common bile duct stones by frequency doubled double pulse Nd:YAG laser. *World J Gastroenterol* 2008;14:2863-6.
121. Adamek HE, Maier M, Jakobs R, et al. Management of retained bile duct stones: a prospective open trial comparing extracorporeal and intracorporeal lithotripsy. *Gastrointest Endosc* 1996;44:40-7.
122. Arya N, Nelles SE, Haber GB, et al. Electrohydraulic lithotripsy in 111 patients: a safe and effective therapy for difficult bile duct stones. *Am J Gastroenterol* 2004;99:2330-4.
123. Swahn F, Edlund G, Enochsson L, et al. Ten years of Swedish experience with intraductal electrohydraulic lithotripsy and laser lithotripsy for the treatment of difficult bile duct stones: an effective and safe option for octogenarians. *Surg Endosc* 2010;24:1011-6.
124. Hui CK, Lai KC, Ng M, et al. Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy. *Aliment Pharmacol Ther* 2003;17:289-96.
125. Neuhaus H, Zillinger C, Born P, et al. Randomized study of intracorporeal laser lithotripsy versus extracorporeal shock-wave lithotripsy for difficult bile duct stones. *Gastrointest Endosc* 1998;47:327-34.
126. Schreiber F, Gurakuqi GC, Trauner M. Endoscopic intracorporeal laser lithotripsy of difficult common bile duct stones with a stone-recognition pulsed dye laser system. *Gastrointest Endosc* 1995;42: 416-9.
127. Neuhaus H, Hoffman W, Gottlieb K, et al. Endoscopic lithotripsy of bile duct stones using a new laser with automatic stone recognition. *Gastrointest Endosc* 1994;40:708-15.
128. Prat F, Fritsch J, Choury AD, et al. Laser lithotripsy of difficult biliary stones. *Gastrointest Endosc* 1994;40:290-5.
129. Tandan M, Reddy DN, Santosh D, et al. Extracorporeal shock wave lithotripsy of large difficult common bile duct stones: efficacy and analysis of factors that favor stone fragmentation. *J Gastroenterol Hepatol* 2009;8:1370-4.
130. Meyenberger C, Meierhofer U, Michel-Harder C, et al. Long-term follow-up after treatment of common bile duct stones by extracorporeal shock-wave lithotripsy. *Endoscopy* 1996;28:411-7.
131. Bland KI, Jones RS, Maher JW, et al. Extracorporeal shock-wave lithotripsy of bile duct calculi. An interim report of the Dornier U.S. Bile Duct Lithotripsy Prospective Study. *Ann Surg* 1989;209:743-53.
132. Jakobs R, Adamek HE, Maier M, et al. Fluoroscopically guided laser lithotripsy versus extracorporeal shock wave lithotripsy for retained bile duct stones: a prospective randomised study. *Gut* 1997;40:678-82.
133. Nicholson DA, Martin DF, Tweedle DE, et al. Management of common bile duct stones using a second-generation extracorporeal shockwave lithotripter. *Br J Surg* 1992;79:811-4.
134. Muratori R, Azzaroli F, Buonfiglioli F, et al. ESWL for difficult bile duct stones: a 15-year single centre experience. *World J Gastroenterol* 2010; 16:4159-63.
135. Ellis RD, Jenkins AP, Thompson RP, et al. Clearance of refractory bile duct stones with extracorporeal shockwave lithotripsy. *Gut* 2000;47: 728-31.
136. Pitt HA, Venbrux AC, Coleman J, et al. Intrahepatic stones: the transhepatic team approach. *Ann Surg* 1994;219:527-37.
137. Yoshimoto H, Ikeda S, Tanaka M, et al. Choledochoscopic electrohydraulic lithotripsy and lithotomy for stones in the common bile duct, intrahepatic ducts, and gallbladder. *Ann Surg* 1989;210:576-82.
138. Liu CL, Fan ST, Wong J. Primary biliary stones: diagnosis and management. *World J Surg* 1998;22:1162-6.

139. Huang MH, Chen CH, Yang JC, et al. Long-term outcome of percutaneous transhepatic cholangioscopic lithotomy for hepatolithiasis. *Am J Gastroenterol* 2003;98:2655-62.
140. Yeh YH, Huang MH, Yang JC, et al. Percutaneous trans-hepatic cholangioscopy and lithotripsy in the treatment of intrahepatic stones: a study with 5 year follow-up. *Gastrointest Endosc* 1995;42:13-8.
141. Lee SK, Seo DW, Myung SJ, et al. Percutaneous transhepatic cholangioscopic treatment for hepatolithiasis: an evaluation of long-term results and risk factors for recurrence. *Gastrointest Endosc* 2001;53:318-23.
142. Uenishi T, Hamba H, Takemura S, et al. Outcomes of hepatic resection for hepatolithiasis. *Am J Surg* 2009;198:199-202.
143. Lee TY, Chen YL, Chang HC, et al. Outcomes of hepatectomy for hepatolithiasis. *World J Surg* 2007;31:479-82.
144. Cheon YK, Cho YD, Moon JH, et al. Evaluation of long-term results and recurrent factors after operative and nonoperative treatment for hepatolithiasis. *Surgery* 2009;146:843-53.
145. Feitoza AB, Baron TH. Endoscopy and ERCP in the setting of previous upper GI tract surgery. Part I: reconstruction without alteration of pancreaticobiliary anatomy. *Gastrointest Endosc* 2001;54:743-9.
146. Feitoza AB, Baron TH. Endoscopy and ERCP in the setting of previous upper GI tract surgery. Part II: postsurgical anatomy with alteration of the pancreaticobiliary tree. *Gastrointest Endosc* 2002;55:75-9.
147. Osnes M, Rosseland AR, Aabakken L. Endoscopic retrograde cholangiography and endoscopic papillotomy in patients with a previous Billroth-II resection. *Gut* 1986;27:1193-8.
148. Hintze RE, Adler A, Veltzke W, et al. Endoscopic access to the papilla of Vater for endoscopic retrograde cholangiopancreatography in patients with Billroth II or Roux-en-Y gastrojejunostomy. *Endoscopy* 1997;29:69-73.
149. Faylona JM, Qadir A, Chan AC, et al. Small-bowel perforations related to endoscopic retrograde cholangiopancreatography (ERCP) in patients with Billroth II gastrectomy. *Endoscopy* 1999;31:546-9.
150. Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. *Gastrointest Endosc* 1998;48:1-10.
151. Morgan KA, Fontenot BB, Ruddy JM, et al. Endoscopic retrograde cholangiopancreatography gut perforations: when to wait! When to operate! *Am Surg* 2009;75:477-83.
152. Gostout CJ, Bender CE. Cholangiopancreatography, sphincterotomy, and common duct stone removal via Roux-en-Y limb enteroscopy. *Gastroenterology* 1988;95:156-63.
153. Elton E, Hanson BL, Qaseem T, et al. Diagnostic and therapeutic ERCP using an enteroscope and a pediatric colonoscope in long-limb surgical bypass patients. *Gastrointest Endosc* 1998;47:62-7.
154. Wright BE, Cass OW, Freeman ML. ERCP in patients with long-limb Roux-en-Y gastrojejunostomy and intact papilla. *Gastrointest Endosc* 2002;56:225-32.
155. Saleem A, Baron TH, Gostout CJ, et al. Endoscopic retrograde cholangiopancreatography using a single-balloon enteroscope in patients with altered Roux-en-Y anatomy. *Endoscopy* 2010;42:656-60.
156. Shimatani M, Matsushita M, Takaoka M, et al. Effective "short" double-balloon enteroscope for diagnostic and therapeutic ERCP in patients with altered gastrointestinal anatomy: a large case series. *Endoscopy* 2009;41:849-54.
157. Itoi T, Ishii K, Sofuni A, et al. Single-balloon enteroscopy-assisted ERCP in patients with Billroth II gastrectomy or Roux-en-Y anastomosis (with video). *Am J Gastroenterol* 2010;105:93-9.
158. Aabakken L, Bretthauer M, Line PD. Double-balloon enteroscopy for endoscopic retrograde cholangiography in patients with a Roux-en-Y anastomosis. *Endoscopy* 2007;39:1068-71.
159. Emmett DS, Mallat DB. Double-balloon ERCP in patients who have undergone Roux-en-Y surgery: a case series. *Gastrointest Endosc* 2007;66:1038-41.
160. Neumann H, Fry LC, Meyer F, et al. Endoscopic retrograde cholangiopancreatography using the single balloon enteroscope technique in patients with Roux-en-Y anastomosis. *Digestion* 2009;80:52-7.
161. Shah RJ, Smolkin M, Ross AS, et al. A multi-center, U.S. experience of single-balloon double-balloon, and rotational overtube enteroscopy-assisted ERCP in long limb surgical bypass patients [abstract]. *Gastrointest Endosc* 2010;71:AB134.
162. Baron TH, Vickers SM. Surgical gastrostomy placement as access for diagnostic and therapeutic ERCP. *Gastrointest Endosc* 1998;48:640-1.
163. Martinez J, Guerrero L, Byers P, et al. Endoscopic retrograde cholangiopancreatography and gastroduodenoscopy after Roux-en-Y gastric bypass. *Surg Endosc* 2006;20:1548-50.
164. Patel JA, Patel NA, Shinde T, et al. Endoscopic retrograde cholangiopancreatography after laparoscopic Roux-en-Y gastric bypass: a case series and review of the literature. *Am Surg* 2008;74:689-93.
165. Gutierrez JM, Lederer H, Krook JC, et al. Surgical gastrostomy for pancreaticobiliary and duodenal access following Roux en Y gastric bypass. *J Gastrointest Surg* 2009;13:2170-5.
166. Lopes TL, Clements RH, Wilcox CM. Laparoscopy-assisted ERCP: experience of a high-volume bariatric surgery center (with video). *Gastrointest Endosc* 2009;70:1254-9.
167. Schäfer M, Schneider R, Krähenbühl L. Incidence and management of Mirizzi syndrome during laparoscopic cholecystectomy. *Surg Endosc* 2003;17:1186-90.
168. Mithani R, Schwesinger WH, Bingener J, et al. The Mirizzi syndrome: multidisciplinary management promotes optimal outcomes. *J Gastrointest Surg* 2008;12:1022-8.
169. Binmoeller KF, Thonke F, Soehendra N. Endoscopic treatment of Mirizzi's syndrome. *Gastrointest Endosc* 1993;39:532-6.
170. Tsuyuguchi T, Saisho H, Ishihara T, et al. Long-term follow-up after treatment of Mirizzi syndrome by peroral cholangioscopy. *Gastrointest Endosc* 2000;52:639-44.
171. Martin DJ, Vernon D, Toouli J. Surgical versus endoscopic treatment of bile duct stones. *Cochrane Database Syst Rev* 2006;19:CD003327.
172. Fanelli RD, Gersin KS. Laparoscopic endobiliary stenting: a simplified approach to the management of occult common bile duct stones. *J Gastrointest Surg* 2001;5:74-80.
173. Cuschieri A, Lezoche E, Moreno M, et al. E.A.E.S. multicenter prospective randomized controlled trial comparing two-stage versus single-stage management of patients with gallstone disease and ductal calculi. *Surg Endosc* 1999;13:952-7.
174. Sgourakis G, Karaliotis K. Laparoscopic common bile duct exploration and cholecystectomy versus endoscopic stone extraction and laparoscopic cholecystectomy for choledocholithiasis: a prospective randomized study. *Minerva Chir* 2002;57:467-74.
175. Noble H, Tranter S, Chesworth T, et al. A randomized, clinical trial to compare endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy with primary laparoscopic bile duct exploration during cholecystectomy in higher risk patients with choledocholithiasis. *J Laparoendosc Adv Surg Tech A* 2009;19:713-20.
176. Nathanson LK, O'Rourke NA, Martin IJ, et al. Postoperative ERCP versus laparoscopic choledochotomy for clearance of selected bile duct calculi. *Ann Surg* 2005;242:188-92.
177. Rhodes M, Sussman L, Cohen L, et al. Randomised trial of laparoscopic exploration of the common bile duct versus postoperative endoscopic retrograde cholangiography for common bile duct stones. *Lancet* 1998;351:159-61.
178. Rogers SJ, Cello JP, Horn JK, et al. Prospective randomized trial of LC+LCBDE vs ERCP/S+LC for common bile duct stone disease. *Arch Surg* 2010;145:28-33.
179. Dias MM, Martin CJ, Cox MR. Pattern of management of common bile duct stones in the laparoscopic era: a NSW survey. *ANZ J Surg* 2002;72:181-5.
180. Spelsberg FW, Nusser F, Hüttl TK, et al. Management of cholecysto- and choledocholithiasis—survey and analysis of 16,615 cholecystectomies and common bile duct explorations in Bavaria [in German]. *Zentralbl Chir* 2009;134:120-6.
181. Bingener J, Schwesinger WH. Management of common bile duct stones in a rural area of the United States: results of a survey. *Surg Endosc* 2006;20:577-9.

182. Speranza V, Fiocca F, Santagati A, et al. Treatment of biliary lithiasis with the advent of new technologies in Italy in the Lazio and Abruzzo regions over the past 15 years. Comparison between the patient series in a Roman university hospital and in a number of hospitals in the Abruzzo region [in Italian]. *Chir Ital* 2004;56:1-10.
183. Navarrete CG, Castillo CT, Castillo PY. Choledocholithiasis: percutaneous treatment. *World J Surg* 1998;22:1151-4.
184. Garcia-Garcia L, Lanciego C. Percutaneous treatment of biliary stones: sphincteroplasty and occlusion balloon for the clearance of bile duct calculi. *AJR Am J Roentgenol* 2004;182:663-70.
185. Hwang MH, Tsai CC, Mo LR, et al. Percutaneous choledochoscopic biliary tract stone removal: experience in 645 consecutive patients. *Eur J Radiol* 1993;17:184-90.
186. Yamakawa T. Percutaneous cholangioscopy for management of retained biliary tract stones and intrahepatic stones. *Endoscopy* 1989;21(Suppl 1):333-7.
187. Ogawa K, Ohkubo H, Abe W, et al. Percutaneous transhepatic small-caliber choledochoscopic lithotomy: a safe and effective technique for percutaneous transhepatic common bile duct exploration in high-risk elderly patients. *J Hepatobiliary Pancreat Surg* 2002;9:213-7.
188. Bonnel DH, Liguory CE, Cornud FE, et al. Common bile duct and intrahepatic stones: results of transhepatic electrohydraulic lithotripsy in 50 patients. *Radiology* 1991;180:345-8.
189. Stokes KR, Falchuk KR, Clouse ME. Biliary duct stones: update on 54 cases after percutaneous transhepatic removal. *Radiology* 1989;170:999-1001.
190. Gil S, de la Iglesia P, Verdú JF, et al. Effectiveness and safety of balloon dilation of the papilla and the use of an occlusion balloon for clearance of bile duct calculi. *AJR Am J Roentgenol* 2000;174:1455-60.
191. Ponchon T, Genin G, Mitchell R, et al. Methods, indications, and results of percutaneous choledochoscopy. A series of 161 procedures. *Ann Surg* 1996;223:26-36.
192. Salvioli G, Salati R, Lugli R, et al. Medical treatment of biliary duct stones: effect of ursodeoxycholic acid administration. *Gut* 1983;24:609-14.
193. Johnson GK, Geenen JE, Venu RP, et al. Treatment of non-extractable common bile duct stones with combination ursodeoxycholic acid plus endoprostheses. *Gastrointest Endosc* 1993;39:528-31.
194. Han J, Moon JH, Koo HC, et al. Effect of biliary stenting combined with ursodeoxycholic acid and terpene treatment on retained common bile duct stones in elderly patients: a multicenter study. *Am J Gastroenterol* 2009;104:2418-21.
195. Katsinelos P, Kountouras J, Paroutoglou G, et al. Combination of endoprostheses and oral ursodeoxycholic acid or placebo in the treatment of difficult to extract common bile duct stones. *Dig Liver Dis* 2008;40:453-9.
196. Palmer KR, Hofmann AF. Intraductal mono-octanoin for the direct dissolution of bile duct stones: experience in 343 patients. *Gut* 1986;27:196-202.
197. Hofmann AF, Schmack B, Thistle JL, et al. Clinical experience with mono-octanoin for dissolution of bile duct stones: an uncontrolled multicenter trial. *Dig Dis Sci* 1981;26:954-5.
198. Murray WR, LaFerla G, Fullarton GM. Choledocholithiasis—in vivo stone dissolution using methyl tertiary butyl ether (MTBE). *Gut* 1988;29:143-5.
199. Kaye GL, Summerfield JA, McIntyre N, et al. Methyl tert butyl ether dissolution therapy for common bile duct stones. *J Hepatol* 1990;10:337-40.
200. Hawes RH, Cotton PB, Vallon AG. Follow-up 6 to 11 years after duodenoscopic sphincterotomy for stones in patients with prior cholecystectomy. *Gastroenterology* 1990;98:1008-12.
201. Prat F, Malak NA, Pelletier G, et al. Biliary symptoms and complications more than 8 years after endoscopic sphincterotomy for choledocholithiasis. *Gastroenterology* 1996;110:894-9.
202. Ando T, Tsuyuguchi T, Okugawa T, et al. Risk factors for recurrent bile duct stones after endoscopic papillotomy. *Gut* 2003;52:116-21.
203. Pereira-Lima JC, Jakobs R, Winter UH, et al. Long-term results (7 to 10 years) of endoscopic papillotomy for choledocholithiasis. Multivariate analysis of prognostic factors for the recurrence of biliary symptoms. *Gastrointest Endosc* 1998;48:457-64.
204. Sugiyama M, Atomi Y. Risk factors predictive of late complications after endoscopic sphincterotomy for bile duct stones: long-term (more than 10 years) follow-up study. *Am J Gastroenterol* 2002;97:2763-7.
205. Costamagna G, Tringali A, Shah SK, et al. Long-term follow-up of patients after endoscopic sphincterotomy for choledocholithiasis, and risk factors for recurrence. *Endoscopy* 2002;34:273-9.
206. Kim DJ, Kim MH, Lee SK, et al. Risk factors for recurrence of primary bile duct stones after endoscopic biliary sphincterotomy. *Gastrointest Endosc* 2001;54:42-8.
207. Keizman D, Shalom MI, Konikoff FM. An angulated common bile duct predisposes to recurrent symptomatic bile duct stones after endoscopic stone extraction. *Surg Endosc* 2006;20:1594-9.
208. Jakobs R, Hartmann D, Kudis V, et al. Risk factors for symptomatic stone recurrence after transpapillary laser lithotripsy for difficult bile duct stones using a laser with a stone recognition system. *Eur J Gastroenterol Hepatol* 2006;18:469-73.
209. Cetta F. The role of bacteria in pigment gallstone disease. *Ann Surg* 1991;213:315-26.
210. Lai KH, Peng NJ, Lo GH, et al. Prediction of recurrent choledocholithiasis by quantitative cholescintigraphy in patients after endoscopic sphincterotomy. *Gut* 1997;41:399-403.
211. Geenen DJ, Geenen JE, Jafri FM, et al. The role of surveillance endoscopic retrograde cholangiopancreatography in preventing episodic cholangitis in patients with recurrent common bile duct stones. *Endoscopy* 1998;30:18-20.
212. Swobodnik W, Janowitz P, Kratzer W, et al. Preventing the recurrence of common bile duct calculi following endoscopic papillotomy with ursodeoxycholic acid. *Z Gastroenterol* 1990;28:621-5.
213. Lygidakis NJ. A prospective randomized study of recurrent choledocholithiasis. *Surg Gynecol Obstet* 1982;155:679-84.
214. Kaminski DL, Barner HB, Codd JE, et al. Evaluation of the results of external choledochoduodenostomy for retained, recurrent, or primary common duct stones. *Am J Surg* 1979;137:162-6.
215. Broughan TA, Sivak MV, Hermann RE. The management of retained and recurrent bile duct stones. *Surgery* 1985;98:746-51.
216. Baker AR, Neoptolemos JP, Leese T, et al. Long term follow-up of patients with side to side choledochoduodenostomy and transduodenal sphincteroplasty. *Ann R Coll Surg Engl* 1987;69:253-7.
217. Uchiyama K, Onishi H, Tani M, et al. Long-term prognosis after treatment of patients with choledocholithiasis. *Ann Surg* 2003;238:97-102.
218. Escudero-Fabre A, Escallon A Jr, Sack J, et al. Choledochoduodenostomy. Analysis of 71 cases followed for 5 to 15 years. *Ann Surg* 1991;213:635-42; discussion 643-4.
219. Parrilla P, Ramirez P, Sanchez Bueno F, et al. Long-term results of choledochoduodenostomy in the treatment of choledocholithiasis: assessment of 225 cases. *Br J Surg* 1991;78:470-2.
220. Gluck M, Cantone NR, Brandabur JJ, et al. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. *J Clin Gastroenterol* 2008;42:1032-9.
221. Okugawa T, Tsuyuguchi T, Sudhamshu KC, et al. Peroral cholangioscopic treatment of hepatolithiasis: long-term results. *Gastrointest Endosc* 2002;56:366-71.
222. Kim MH, Lee SK, Lee MH, et al. Endoscopic retrograde cholangiopancreatography and needle-knife sphincterotomy in patients with Billroth II gastrectomy: a comparative study of the forward-viewing endoscope and the side-viewing duodenoscope. *Endoscopy* 1997;29:82-5.
223. Lopes TL, Wilcox CM. Endoscopic retrograde cholangiopancreatography in patients with Roux-en-Y anatomy. *Gastroenterol Clin N Am* 2010;39:99-107.

224. England RE, Martin DF. Endoscopic management of Mirizzi's syndrome. *Gut* 1997;40:272-6.

---

Prepared by:

ASGE STANDARDS OF PRACTICE COMMITTEE

John T. Maple, DO

Steven O. Ikenberry, MD

Michelle A. Anderson, MD

Vasundhara Appalaneni, MD

G. Anton Decker, MD

Dayna Early, MD

John A. Evans, MD

Robert D. Fanelli, MD, SAGES Representative

Deborah Fisher, MD

Laurel Fisher, MD

Norio Fukami, MD

Joo Ha Hwang, MD

Rajeev Jain, MD

Terry Jue, MD

Khalid Khan, MD, NASPAGHAN Representative

Mary Lee Krinsky, DO

Phyllis Malpas, RN, SGNA Representative

Tamir Ben-Menachem, MD

Ravi N. Sharaf, MD

Jason A. Dominitz, MD, MHS, Committee Chair

This document is a product of the Standards of Practice Committee. This document was reviewed and approved by the Governing Board of the American Society for Gastrointestinal Endoscopy.

---

### Online Audio and Podcasting

Audio and Podcasts of article abstracts published in *Gastrointestinal Endoscopy* are now available online. Recordings are edited by Ian Gralnek, MD, MSHS, Senior Associate Editor, and performed by Deborah Bowman, MFA, Managing Editor of *Gastrointestinal Endoscopy*.

Log on to [www.giejournal.org](http://www.giejournal.org) to listen to recordings from the current issue.